

subcontractors who were monitored or should have been monitored for exposure to ionizing radiation associated with radioactive lanthanum (RaLa) operations at Technical Area 10 (Bayo Canyon Site), Technical Area 35 (Ten Site), and Buildings H, Sigma, and U (located within Technical Area 1) for a number of work days aggregating at least 250 work days during the period from September 1, 1944, through July 18, 1963, or in combination with work days within the parameters established for one or more classes of employees in the SEC.

This designation will become effective on December 9, 2006, unless Congress provides otherwise prior to the effective date. After this effective date, HHS will publish a notice in the **Federal Register** reporting the addition of this class to the SEC or the result of any provision by Congress regarding the decision by HHS to add the class to the SEC.

Pursuant to 42 U.S.C. § 7384q, in a October 11, 2006 letter to the Secretary of HHS, the Advisory Board on Radiation and Worker Health (“the Board”) advised the Secretary of HHS to designate the class as an addition to the SEC. The Board further stated,

“In their evaluation, NIOSH determined that it was difficult to identify people who worked in these areas of LANL based on job classifications. Therefore, the Board recommends that determination of eligibility for this class take into account this difficulty and in the absence of work history or other information to the contrary, workers at the LANL facility during the period in question should be presumed to have worked in the areas in question.”

Since determination of eligibility is not within the authority of HHS, the Board’s recommendation on this issue was not included in the HHS designation.

**FOR FURTHER INFORMATION CONTACT:**

Larry Elliott, Director, Office of Compensation Analysis and Support, National Institute for Occupational Safety and Health, 4676 Columbia Parkway, MS C-46, Cincinnati, OH 45226, Telephone 513-533-6800 (this is not a toll-free number). Information requests can also be submitted by e-mail to [OCAS@CDC.GOV](mailto:OCAS@CDC.GOV).

Dated: November 30, 2006.

**John Howard,**

*Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.*

[FR Doc. 06-9587 Filed 12-7-06; 8:45 am]

**BILLING CODE 4160-17-M**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Designation of a Class of Employees for Addition to the Special Exposure Cohort**

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services (HHS) gives notice of a decision to designate a class of employees at the Oak Ridge Thermal Diffusion Plant (S-50), Oak Ridge, Tennessee, as an addition to the Special Exposure Cohort (SEC) under the Energy Employees Occupational Illness Compensation Program Act of 2000. On November 9, 2006, the Secretary of HHS designated the following class of employees as an addition to the SEC:

Employees of the Department of Energy predecessor agencies and their contractors and subcontractors who were monitored or should have been monitored while working at the S-50 Oak Ridge Thermal Diffusion Plant working for a number of work days aggregating at least 250 work day during the period from July 9, 1944, through December 31, 1951, or in combination with work days within the parameters established for one or more other classes of employees in the SEC.

This designation will become effective on December 9, 2006, unless Congress provides otherwise prior to the effective date. After this effective date, HHS will publish a notice in the **Federal Register** reporting the addition of this class to the SEC or the result of any provision by Congress regarding the decision by HHS to add the class to the SEC.

**FOR FURTHER INFORMATION CONTACT:**

Larry Elliott, Director, Office of Compensation Analysis and Support, National Institute for Occupational Safety and Health, 4676 Columbia Parkway, MS C-46, Cincinnati, OH 45226, Telephone 513-533-6800 (this is not a toll-free number). Information requests can be submitted by e-mail to [OCAS@CDC.GOV](mailto:OCAS@CDC.GOV).

Dated: November 30, 2006.

**John Howard,**

*Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.*

[FR Doc. 06-9588 Filed 12-7-06; 8:45 am]

**BILLING CODE 4160-17-M**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Advisory Committee on Immunization Practices: Meeting**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following Federal Committee meeting.

*Name:* Advisory Committee on Immunization Practices (ACIP).

*Times and Dates:* 8 a.m.–6 p.m., February 21, 2007, 8 a.m.—4 p.m., February 22, 2007.

*Place:* Centers for Disease Control and Prevention, 1600 Clifton Road, NE., Global Communications Center, Building 19, Room 232, Atlanta, Georgia 30333.

*Status:* Open to the public, limited only by the space available. Meeting space accommodates approximately 330 people. Overflow space for real-time viewing will be available.

*Purpose:* The Committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. § 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines.

*Matters to be Discussed:* The agenda will include discussions on influenza vaccine; immunization safety; update on use of rotavirus vaccine; update on use of HPV vaccine; update on use of herpes zoster (shingles) vaccine; vaccine supply; Japanese encephalitis and other flavivirus vaccines (e.g., yellow fever vaccine); diphtheria, tetanus, pertussis, polio, Haemophilus B [Hib] combination vaccine (Pentacel®); evidence-based recommendations; and agency updates.

Agenda items are subject to change as priorities dictate.

*Additional Information:* In order to expedite the security clearance process at the CDC Roybal Campus located on Clifton Road, all ACIP attendees are required to register on line at [www.cdc.gov/nip/acip](http://www.cdc.gov/nip/acip), which can be found at the “Upcoming Meetings” tab. Please complete all the required fields before submitting your registration and submit no later than January 18, 2007.

**Please Note:** In addition to completing the registration form on line, as described above, all non-U.S. citizens are required to complete the “Access Request Form.” The completed access request form should be sent by e-mail directly to Ms. Gardner at [dgardner@cdc.gov](mailto:dgardner@cdc.gov).

*Contact Person for More Information:* Demetria Gardner, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road, NE, (E-05), Atlanta, Georgia 30333, telephone 404/639-8836, fax 404/639-6258.